SQZ Biotechnologies EBITDA Margin 2020-2023 | SQZ

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current EBITDA margin for SQZ Biotechnologies as of March 31, 2023 is .
SQZ Biotechnologies EBITDA Margin Historical Data
2022-12-31 $0.02B $-0.07B -328.57%
2022-09-30 $0.02B $-0.07B -319.05%
2022-06-30 $0.02B $-0.07B -291.30%
2022-03-31 $0.03B $-0.06B -252.00%
2021-12-31 $0.03B $-0.06B -214.81%
2021-09-30 $0.02B $-0.06B -376.47%
2021-06-30 $0.02B $-0.05B -300.00%
2021-03-31 $0.02B $-0.05B -236.84%
2020-12-31 $0.02B $-0.04B -200.00%
2020-06-30 $0.02B $-0.02B -143.75%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.016B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.206B 8.38
GSK (GSK) United Kingdom $71.088B 9.92
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.347B 21.85
Ginkgo Bioworks Holdings (DNA) United States $3.670B 0.00
Arcus Biosciences (RCUS) United States $1.582B 0.00
Biohaven (BHVN) United States $1.578B 0.00
Emergent Biosolutions (EBS) United States $0.423B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.192B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00